RxDoctor Payments Data

Valeria Perruci, MD

Internal Medicine · Clearwater, FLNPI 1881815447

Payments from drug & device makers

$527in general payments, 2019–2025

Across 19 payments — averaging $27.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$251
  • Exact Sciences$111
  • Merck$37
  • AstraZeneca$37
  • Lilly USA, LLC$35
  • Phathom Pharmaceuticals, Inc.$23
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$527100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$527 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$139,538
Medicare patients
330
Services billed
1,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$46,085
XareltoRivaroxaban25$31,465
FarxigaDapagliflozin Propanediol21$20,793
JanuviaSitagliptin Phosphate11$16,000
Atorvastatin Calcium656$6,258
Rosuvastatin Calcium405$5,204
SynthroidLevothyroxine Sodium49$4,783
Losartan Potassium340$3,527
Omeprazole241$3,503
CrestorRosuvastatin Calcium11$3,468
Levothyroxine Sodium353$3,468
Escitalopram Oxalate196$2,876
EdarbiAzilsartan Medoxomil11$2,766
Gabapentin141$2,743
Wixela InhubFluticasone Propion/Salmeterol15$2,431

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Crestor$37$24,26132 claims
MerckJanuvia$37$16,00011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →